Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug XmAb27564 tested for skin conditions – trial halted early

NCT ID NCT06005792

Disease control Sponsor: Xencor, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called XmAb27564 in 23 people with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants received four doses of the drug or a placebo every two weeks. The main goal was to check safety and tolerability. The study was terminated, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
XmAb27564
What this could lead to
If successful, this could point toward a new treatment option for plaque psoriasis and atopic dermatitis.
What could go wrong
This was a very early (Phase 1) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

23 people

The number who actually took part.

Started

Oct 2022

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion and exclusion criteria include, but are not limited to, the following: * Have active mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis according to study-specific criteria * Weight between 40 to 150 kg, inclusive * No topical treatments for psoriasis or atopic dermatitis for 2 weeks before randomization * No phototherapy for psoriasis for 4 weeks before randomization * Washout of oral treatments for psoriasis or atopic dermatitis for 4 weeks before randomization * Washout of biologic treatments for psoriasis or atopic dermatitis for 12 weeks before randomization * Stated willingness to comply with all study procedures (including skin biopsies) and availability for the duration of the study Exclusion Criteria: * Patients with a history of active asthma within 5 years of screening, except those that have well controlled asthma symptoms at screening visit. * Patients who have had any prior investigational treatment with IL-2 therapies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Psoriasis

Contacts and locations

Locations

  • Center for Clinical Studies, LTD. LLP

    Webster, Texas, 77598, United States

  • Clinical Trials Research Institute

    Thousand Oaks, California, 91320, United States

  • Driven Research

    Coral Gables, Florida, 33134, United States

  • Innovaderm Research Inc.

    Montreal, Quebec, H2X 2V1, Canada

  • J&S Studies, Inc

    College Station, Texas, 77845, United States

  • San Marcus Research Clinic

    Miami Lakes, Florida, 33104, United States

  • Unison Clinical Trials

    Sherman Oaks, California, 91403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.